Lin Ji-Fan, Lin Yi-Chia, Tsai Te-Fu, Chen Hung-En, Chou Kuang-Yu, Hwang Thomas I-Sheng
Central Laboratory, Shin Kong Wu Ho-Su Memorial Hospital, Taipei.
Division of Urology, School of Medicine, Fu-Jen Catholic University, New Taipei.
Drug Des Devel Ther. 2017 May 16;11:1517-1533. doi: 10.2147/DDDT.S126464. eCollection 2017.
Cisplatin-based chemotherapy is the first line treatment for several cancers including bladder cancer (BC). Autophagy induction has been implied to contribute to cisplatin resistance in ovarian cancer; and a high basal level of autophagy has been demonstrated in human bladder tumors. Therefore, it is reasonable to speculate that autophagy may account for the failure of cisplatin single treatment in BC. This study investigated whether cisplatin induces autophagy and the mechanism involved using human BC cell lines.
Human BC cells (5637 and T24) were used in this study. Cell viability was detected using water soluble tetrazolium-8 reagents. Autophagy induction was detected by monitoring the levels of light chain 3 (LC3)-II and p62 by Western blot, LC3-positive puncta formation by immunofluorescence, and direct observation of the autophagolysosome (AL) formation by transmission electron microscopy. Inhibitors including bafilomycin A1 (Baf A1), chloroquine (CQ), and shRNA-based lentivirus against autophagy-related genes (ATG7 and ATG12) were utilized. Apoptosis level was detected by caspase 3/7 activity and DNA fragmentation.
Cisplatin decreased cell viability and induced apoptosis of 5637 and T24 cells in a dose-and time-dependent manner. The increased LC3-II accumulation, p62 clearance, the number of LC3-positive puncta, and ALs in cisplatin-treated cells suggested that cisplatin indeed induces autophagy. Inhibition of cisplatin-induced autophagy using Baf A1, CQ, or ATG7/ATG12 shRNAs significantly enhanced cytotoxicity of cisplatin toward BC cells. These results indicated that cisplatin induced protective autophagy which may contribute to the development of cisplatin resistance and resulted in treatment failure. Mechanistically, upregulation of beclin-1 (BECN1) was detected in cisplatin-treated cells, and knockdown of BECN1 using shRNA attenuated cisplatin-induced autophagy and subsequently enhanced cisplatin-induced apoptosis.
Collectively, the study results indicated that cisplatin-induced autophagy is mediated by BECN1 in BC cells. Therefore, combinative treatment using cisplatin and autophagy inhibitors could potentially overcome cisplatin resistance related to autophagy induction.
基于顺铂的化疗是包括膀胱癌(BC)在内的多种癌症的一线治疗方法。自噬诱导被认为与卵巢癌的顺铂耐药有关;并且在人类膀胱肿瘤中已证实自噬的基础水平较高。因此,合理推测自噬可能是顺铂单药治疗BC失败的原因。本研究使用人BC细胞系研究顺铂是否诱导自噬及其相关机制。
本研究使用人BC细胞(5637和T24)。使用水溶性四氮唑-8试剂检测细胞活力。通过蛋白质免疫印迹法监测轻链3(LC3)-II和p62的水平、免疫荧光法检测LC3阳性斑点的形成以及透射电子显微镜直接观察自噬溶酶体(AL)的形成来检测自噬诱导。使用了包括巴弗洛霉素A1(Baf A1)、氯喹(CQ)以及针对自噬相关基因(ATG7和ATG12)的基于短发夹RNA(shRNA)的慢病毒等抑制剂。通过半胱天冬酶3/7活性和DNA片段化检测凋亡水平。
顺铂以剂量和时间依赖性方式降低5637和T24细胞的活力并诱导其凋亡。顺铂处理的细胞中LC3-II积累增加、p62清除、LC3阳性斑点数量以及AL增加,表明顺铂确实诱导自噬。使用Baf A1、CQ或ATG7/ATG12 shRNAs抑制顺铂诱导的自噬显著增强了顺铂对BC细胞的细胞毒性。这些结果表明顺铂诱导了保护性自噬,这可能导致顺铂耐药的产生并导致治疗失败。机制上,在顺铂处理的细胞中检测到beclin-1(BECN1)上调,使用shRNA敲低BECN1可减弱顺铂诱导的自噬并随后增强顺铂诱导的凋亡。
总体而言,研究结果表明顺铂诱导的自噬在BC细胞中由BECN1介导。因此,顺铂与自噬抑制剂联合治疗可能潜在地克服与自噬诱导相关的顺铂耐药。